Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Blood Cancer J. 2023 Dec 11;13(1):183. doi: 10.1038/s41408-023-00957-w.

Authors

Charalampos Charalampous¹, Utkarsh Goel¹, Prashant Kapoor¹, Moritz Binder¹, Francis K Buadi¹, Joselle Cook¹, David Dingli¹, Angela Dispenzieri¹, Amie L Fonder¹, Morie A Gertz¹, Wilson Gonsalves¹, Suzanne R Hayman¹, Miriam A Hobbs¹, Yi L Hwa¹, Taxiarchis Kourelis¹, Martha Q Lacy¹, Nelson Leung², Yi Lin¹, Rahma Warsame¹, Robert A Kyle¹, S Vincent Rajkumar¹, Shaji K Kumar³

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
³ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. [email protected].

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasms, Plasma Cell*

Substances

daratumumab
Antibodies, Monoclonal
Dexamethasone

Grants and funding

P50 CA186781/CA/NCI NIH HHS/United States